RxDoctor Payments Data

Samuel Landero, MD

Family Medicine · Harlingen, TXNPI 1396019642

Payments from drug & device makers

$2,023,558in general payments, 2019–2025

Across 151 payments — averaging $13,401 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1M
  • Astrazeneca UK Limited$695K
  • AbbVie$102K
  • Radius Health, Inc.$98K
  • Lexicon Pharmaceuticals, Inc.$69K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$13K
  • plus $629 from 6 others
$1,831in research payments, 2019–2025

Across 3 payments — averaging $610.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lexicon Pharmaceuticals, Inc.$2K

What the payments were for

  • Travel & lodging$1,84364%
  • Food & beverage$1,02236%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023,558 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$166,420
Medicare patients
207
Services billed
2,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$86,533
JardianceEmpagliflozin58$57,731
MounjaroTirzepatide38$38,429
TrulicityDulaglutide23$28,251
Tresiba Flextouch U-200Insulin Degludec27$25,411
Soliqua 100-33Insulin Glargine/Lixisenatide16$20,728
Breo ElliptaFluticasone/Vilanterol25$15,212
XareltoRivaroxaban13$12,360
LinzessLinaclotide14$10,936
Tresiba Flextouch U-100Insulin Degludec16$10,170
BelsomraSuvorexant15$6,693
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,183
Testosterone13$3,101
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen108$2,857
Levothyroxine Sodium236$2,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$407$86,53380 claims
Lilly USA, LLCMounjaro, Trulicity$113$66,68061 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$17$20,72816 claims
AbbVieLinzess, Synthroid$102,070$13,00149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →